Results 101 to 110 of about 9,605 (202)

European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time.
Konstantin Tachkov, Merita Rumano, James Bluett, Nataša Bogavac‐Stanojević, Erwin Dreesen, Mehmet Itik, Georgios Kararigas, Paweł Kawalec, Marlene Santos, Silje Skrede, Guenka Petrova, Denis Mulleman   +11 more
wiley   +1 more source

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Drug Design, Development and Therapy, 2017
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M   +5 more
doaj  

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 6, Page 737-744, June 2026.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen, Ruben Heuer, Brit Haecker, Tom Schaberg, Alexander Nast   +4 more
wiley   +1 more source

Biosimilars and haemophilia [PDF]

Haemophilia, 2018
openaire   +2 more sources

Uneinheitliche Standards beim Tuberkulose‐Screening und der präventiven Tuberkulosetherapie vor Beginn einer systemischen Psoriasistherapie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 6, Page 737-745, June 2026.
Zusammenfassung Hintergrund und Ziele Die präventive Therapie einer Tuberkulose (TB) vor der Einleitung von Methotrexat (MTX) oder IL‐17/IL‐23/IL‐12/23p40‐Inhibitoren bei latenter Tuberkuloseinfektion (LTBI) wird indirekt durch ein nachweislich erhöhtes TB‐Reaktivierungsrisiko unter TNF‐Inhibitoren gestützt.
Christoph Zeyen, Ruben Heuer, Brit Haecker, Tom Schaberg, Alexander Nast   +4 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 963-979, June 2026.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Biosimilar medicines and cost-effectiveness

ClinicoEconomics and Outcomes Research, 2011
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj  

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj  

Intravitreal Anti-VEGF Injection Transitions Across Bevacizumab, Biosimilar, and Branded Medications: The IRIS Registry Study. [PDF]

J Vitreoretin Dis
Berkowitz ST, Gilbert JB, Ross CJ, Kearney WC, Lorch A, Miller JW, Rossin EJ, Sternberg P, Finn AP.   +8 more
europepmc   +1 more source